Andrew Huberman said the FDA's last review of MDMA-assisted psychotherapy for PTSD failed for reasons that had little to do with the drug itself and everything to do with how the treatment was run. He said the review ran into an inadequate control condition and therapist sexual improprieties, and that one such incident can sink an entire initiative.
That explanation is drawing attention now because the treatment was not presented as a marginal experiment. Huberman said the sessions used body-weight-scaled doses of roughly 80 milligrams with a 50-milligram booster, spaced about three weeks apart, with talk therapy before, during, and after the sessions. In some cases, he said, the result was a 60, 70% significant reduction in symptoms, and even remission. For readers searching Andrew Huberman today, that is the central split: strong reported response on one side, a failed regulatory review on the other.
Huberman also said there is no evidence that MDMA is neurotoxic, and he pointed to a landmark study published in Science on non-human primates that he said was retracted after the laboratory accidentally injected methamphetamine, not MDMA. He said methamphetamine creates probably the largest dump of dopamine in the brain in the short term, which is part of why he treats that mix-up as more than a footnote. In his telling, the old claim that MDMA burns holes in the brain helped shape decades of anti-drug messaging, even as the clinical case for the therapy kept moving forward.
The friction is that the science did not fail cleanly. Huberman said the problem was not simply whether patients in MDMA-assisted psychotherapy could improve, but whether the field can prove that the improvement came from a therapy that was safe, consistent, and restrained enough to satisfy the FDA. He said psychedelic-assisted therapy still has no formalized standards for what happens during a session, and he raised the hard questions that follow from that gap: what to say when intense feelings surface, whether to push through pain or step back, and how much of the process is still done by feel. That is where the approval question now sits.
Huberman said the MDMA therapy submission may pass in a subsequent round if safeguards are put in place to ensure safe administration. He added that psychedelic-assisted therapy needs clearer rules around conduct, because one incident like the ones he described can stop the entire effort. For patients waiting on MDMA-assisted treatment for PTSD, the next hurdle is not proving that some people can get better. It is proving the sessions can be run in a way that no regulator has reason to reject.
